[G protein-coupled receptors: allosteric regulators of cell metabolism].

Med Sci (Paris)

Département biotechnologie et signalisation cellulaire, Université de Strasbourg, École supérieure de biotechnologie de Strasbourg, Illkirch Cedex, France.

Published: October 2012

Fifty years ago, the first successful isolation of enzymes and the study of their reaction mechanisms challenged biochemists to investigate their biological regulation. Various models have been proposed on the basis of available catalytical, pharmacological and structural information. The "allosteric model" of Monod, Wyman and Changeux describes regulatory proteins that can adopt multiple interconvertible conformations, differently stabilized by substrates, products and allosteric effectors. These effectors target regulatory sites topographically distinct from the enzymatic reaction center. Each conformational state is characterized by a unique set of pharmacological, functional and structural properties. The oligomeric nature of the proteins which were used to construct this model allowed to describe an important phenomenon, referred to as cooperativity. It explains how the binding of a molecule to one subunit of the protein can facilitate, or conversely impede, the binding of a second molecule to a neighboring subunit. This concept has evolved and now extends to allosteric regulatory phenomena dealing with distinct effectors that bind to their own sites on a monomeric protein, such as a G-protein coupled receptor. This article focuses on G-protein-coupled receptors and aims to discuss (1) how their functional architecture meets the rules of allostery, and (2) how allosteric effectors (small molecules or cell components), with which the receptors establish stable or transient interactions, may cooperate to finely tune their pharmacological and functional properties.

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20122810013DOI Listing

Publication Analysis

Top Keywords

allosteric effectors
8
pharmacological functional
8
protein-coupled receptors
4
allosteric
4
receptors allosteric
4
allosteric regulators
4
regulators cell
4
cell metabolism]
4
metabolism] fifty
4
fifty years
4

Similar Publications

Protein catalysis and allostery require the atomic-level orchestration and motion of residues and ligand, solvent and protein effector molecules. However, the ability to design protein activity through precise protein-solvent cooperative interactions has not yet been demonstrated. Here we report the design of 14 membrane receptors that catalyse G protein nucleotide exchange through diverse engineered allosteric pathways mediated by cooperative networks of intraprotein, protein-ligand and -solvent molecule interactions.

View Article and Find Full Text PDF

The complexity of allosteric enzymatic regulation continues to inspire synthetic chemists seeking to emulate interconnected biological systems. In this work, a Pt2L4 cage capable of catalyzing the cyclization reaction of an alkynoic tosyl amide is orthogonally coupled to a diacid-catalyzed carbodiimide-hydration cycle. This new Pt-catalyzed cyclization reaction is demonstrated to exhibit electronic regulation by inclusion of different guest effectors.

View Article and Find Full Text PDF

The hypoxic microenvironment is crucial for tumour cell growth and invasiveness. Tumour tissue results from adaptation to reduced oxygen availability. Hypoxia first activates pro-angiogenic signals for alleviation.

View Article and Find Full Text PDF

Type III clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) systems (type III CRISPR-Cas systems) use guide RNAs to recognize RNA transcripts of foreign genetic elements, which triggers the generation of cyclic oligoadenylate (cOA) second messengers by the Cas10 subunit of the type III effector complex. In turn, cOAs bind and activate ancillary effector proteins to reinforce the host immune response. Type III systems utilize distinct cOAs, including cyclic tri- (cA3), tetra- (cA4) and hexa-adenylates (cA6).

View Article and Find Full Text PDF

The chitinase-like protein YKL-40 (CHI3L1) has been implicated in the pathophysiology of inflammation and cancer. Recent studies highlight the growing interest in targeting and blocking the activity of YKL-40 to treat cancer. Some of those targeting-strategies have been developed to directly block the heparin-affinity of YKL-40 with promising results.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!